VJHemOnc Podcast

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Tanya Siddiqi, MD, City of Hope, Duarte, CA, and Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discuss the role of BTK inhibitors and degraders in NHL. Following this, you will hear from Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, and Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, who discuss the growing role of bispecific antibodies, including glofitamab, epcoritamab and odronextamab, in this disease setting.

In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in this disease. Early and accurate diagnosis present a key challenge, and both clinicians and researchers are investigating novel strategies with the aim of improving outcomes for patients. 

In this podcast, Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Efstathios Kastritis, MD, University of Athens, Athens, Greece, discuss unmet needs in AL amyloidosis, as well as novel immunotherapy strategies being explored. The experts also highlight the prevalence of clonal hematopoiesis of indeterminate potential (CHIP) in this disease setting.

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, John Gribben, MD, DSc, FRCPath, FRCP, FMedSci, Barts Cancer Institute, London, UK, Laurie Sehn, MD, University of British Columbia, Vancouver, Canada, Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, and Sven De Vos, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA, discuss novel therapies in NHL, drawing focus on the role of antibody-drug conjugates (ADCs).

The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diagnosis and risk stratification of patients.

In this podcast, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, and John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, discuss several updates in the field of MPNs. Topics covered include novel agents being explored in PV, clinical guidance for the use of JAK inhibitors in MF, and the growing role of combination approaches.

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marek Trněný, MD, PhD, Charles University, Prague, Czech Republic, John Kuruvilla, MD, Princess Margaret Cancer Centre, Toronto, Canada, and Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, share some insights into the evolving treatment landscape in mantle cell lymphoma (MCL), commenting on the changing role of transplantation and the impact of novel agents.

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Francine Foss, MD, Yale School of Medicine, New Haven, CT, Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, Francois Lemonnier, MD, PhD, Henri Mondor University Hospital, Créteil, France, and Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discuss recent updates in the biology and treatment of T-cell lymphoma.

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, discuss the most recent updates in transplantation and immunotherapies in AML, and further comment on how to improve outcomes for patients.

While the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several challenges associated with treating elderly patients in these disease settings. The presence of comorbidities, as well as the risk of treatment-related toxicities, makes the treatment of elderly patients an important area of research.

In this podcast, Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, and Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, discuss challenges with classifying frailty in elderly patients with diffuse large B-cell lymphoma (DLBCL) and HL, as well as treatment options available to these patients.

The treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are being conducted with the goal of improving the understanding of this disease. Furthermore, there have been recent updates to classification systems for MDS, including the Molecular International Prognostic Scoring System (IPSS-M). 

In this podcast, you will hear from Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, who discuss recent updates in the diagnosis, risk stratification and treatment of LR-MDS. This discussion was filmed at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Andrew Wei, MBBS, PhD, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Australia, and Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the relevance of TP53 mutation in AML, highlighting prognostic approaches and therapeutic strategies for this patient population.